AI Drug Discovery: Front & Back– category –
-
The Future of Pharmacovigilance: AI and Machine Learning Reshaping Adverse-Event Detection Across 3 Axes | Vol.5 (Final)
AI in pharmacovigilance — FDA/PMDA initiatives, social media and EHR-based signal detection, the future of drug safety. -
How Virtual Trials Will Reshape Clinical Development: Digital Twins and In Silico Cohorts at 5 Turning Points | Vol.4
Virtual trials and in silico cohorts at Pfizer, Sanofi and beyond — will digital twins truly transform clinical trials? -
How Mechanistic Modeling × AI Closes the Preclinical-to-Clinical Gap: 3 Axes of Translational Acceleration | Vol.3
Mechanistic modeling × AI for preclinical-to-clinical translation: PBPK, QSP, and digital twin frontiers. -
How Compound Management Reshaped Drug Discovery: 3 Axes of AI × Robotics-Driven Asset Reuse | Vol.2
How AI and robotics are transforming compound management — the quiet revolution that actually moves pharma P/L. -
Reading AI Drug Discovery’s Two Layers: 5-Company Map of Headlines vs Operational Transformation | Vol.1
AI drug discovery company map (Insilico, Recursion, Isomorphic Labs, Schrodinger) and the real profit structure transformation behind the headlines.
1